Skip to main content
main-content

01.12.2017 | Research article | Ausgabe 1/2017 Open Access

BMC Cancer 1/2017

The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients

Zeitschrift:
BMC Cancer > Ausgabe 1/2017
Autoren:
Shengjie Guo, Xiaobo He, Qian Chen, Guangwei Yang, Kai Yao, Pei Dong, Yunlin Ye, Dong Chen, Zhiling Zhang, Zike Qin, Zhuowei Liu, Yunfei Xue, Meng Zhang, Ruiwu Liu, Fangjian Zhou, Hui Han
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12885-017-3119-6) contains supplementary material, which is available to authorized users.
Abbreviations
ALP
Alkaline phosphatase
BMI
Body mass index
CI
Confidence interval
CRE
Serum creatinine
CRP/Alb
C-reactive protein/Albumin
DFS
Disease-free survival
GPS
Glasgow prognostic score
HR
Hazard ratio
LDH
Lactate dehydrogenase
NLR
Neutrophil count to lymphocyte count ratio
OS
Overall survival
PLR
Platelet count to lymphocyte count ratio
RCC
Renal cell cancer
UA
Uric acid

Background

Renal cell carcinoma (RCC) is the most common malignancy in females with urological tumors and ranks the third place in males after prostate and bladder cancers [ 1]. Broad applications of radiological technologies especially abdominal ultrasound or computerized tomography have led to increase in detection of renal tumors in relatively small size and localized in the kidney [ 2]. Patients with localized diseases usually undergo curative whole or partial nephrectomy. However, up to 40% patients will eventually relapse with secondary tumors at distant sites [ 3, 4]. At first presentation, one-third of all RCC patients will have established metastatic renal cell carcinoma (mRCC). Despite the introduction of molecular targeted therapies, the overall 5-year survival rate of this patient group rarely exceeds 10% [ 5, 6]. In addition, RCC is characterized by chemo- and radio-resistance. The clinical course in localized RCC is difficult to predict, even within patients who have similar clinic-pathological parameters, such as tumor stage and grade [ 7, 8]. Therefore, it is important to identify promising prognostic factors to guide patient management after curative surgery treatment.
Increasing evidences have demonstrated the role of inflammation in carcinogenesis and tumor progression. The prognostic value of many inflammation-based scores, such as preoperative C-reactive protein (CRP), the Glasgow Prognostic Score (GPS), modified Glasgow prognostic score (mGPS), high-sensitivity modified Glasgow prognostic score (HS-mGPS), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), has been validated in many types of cancer, including RCC [ 913]. Additionally, some studies have demonstrated that the preoperative nutritional status, such as hypoalbuminemia, weight loss and low body mass index (BMI), are associated with worse outcomes of RCC patients after radical or partial nephrectomy [ 14, 15]. Recently, a new prognostic index, preoperative C-reactive protein/albumin (CRP/Alb) ratio, in combination with the systemic inflammation and nutritional status, has also been reported as an independent prognostic marker in hepatocellular cancer (HCC), gastric cancer (GC) and small-cell lung cancer (SCLC) [ 1618]. Although Chen et al. reported the prognostic influence of CRP/Alb ratio on overall survival (OS) of patients with clear cell renal carcinoma [ 19], its prognostic role in RCC still need to be further explored. In this retrospective study, we examined the prognostic value of CRP/Alb ratio in patients with RCC and investigated the relationship between CRP/Alb ratio and the clinical outcomes of RCC patients.

Methods

Patients

We executed a retrospective cohort study of 912 consecutive RCC patients who underwent radical or partial nephrectomy between January 2000 and December 2012 in Sun Yat-sen University Cancer Center (SYSUCC). The inclusion criteria were as follows: 1) patients were cytologically or histologically diagnosed with RCC; 2) data on complete blood laboratory measurements included serum CRP and albumin (Alb) within one week before performing radical or partial nephrectomy. Patients without blood laboratory measurements prior to surgical resection, patients with active inflammatory disease and patients with other malignancies were excluded from the study. At last, a total of 570 patients were enrolled in the study. This retrospective study was conducted in accordance with the standards of the Declaration of Helsinki and was approved by the Sun Yat-sen University Cancer Center research ethics committee (Number: GZR2016-100). All patients have provided written informed consent for their information to be stored and used in the hospital database.

Clinical data extraction

The baseline clinical and pathologic characteristics were collected, including age at the time of surgery, gender, BMI, lactate dehydrogenase (LDH), urine protein, alkaline phosphatase (ALP), serum creatinine (CRE), uric acid (UA), total protein, serum globulin, neutrophil count, lymphocyte count, platelet count, disease stage and histology by using a standard data extraction system. Elevated ALP level was defined as serum ALP > 135 U/L. Elevated LDH was defined as serum LDH > 245 U/L. Elevated CRE was defined as serum CRE > 130 μmol/L. Elevated UA was defined as UA > 420 μmol/L. Elevated total protein was as total protein > 80 g/L. Elevated globulin was defined as globulin > 35 g/L. Tumor stage was determined based on the 2010 TNM classification of malignant tumors staging system and tumor grade was defined according to the Fuhrman grading system. All the blood samples were tested prior to initial treatment. The NLR, PLR and CRP/Alb ratio were calculated based on the following equations, respectively.
$$ \mathrm{N}\mathrm{L}\mathrm{R} = \kern0.5em \mathrm{neutrophil}\ \mathrm{count}\ \mathrm{t}\mathrm{o}\ \mathrm{lymphocyte}\ \mathrm{count}, $$
$$ \mathrm{P}\mathrm{L}\mathrm{R} = \mathrm{platelet}\ \mathrm{count}\ \mathrm{t}\mathrm{o}\ \mathrm{lymphocyte}\ \mathrm{count}, $$
$$ \mathrm{C}\mathrm{R}\mathrm{P}/\mathrm{Alb}=\mathrm{t}\mathrm{he}\ \mathrm{serum}\ \mathrm{C}\mathrm{R}\mathrm{P}\ \mathrm{level}\ \mathrm{t}\mathrm{o}\ \mathrm{t}\mathrm{he}\ \mathrm{serum}\ \mathrm{Alb}\ \mathrm{level}. $$

Patients follow-up

A dynamic computed tomogram was performed every 3 months in two years, 6 months in 2–5 years and 1 year after 5 years. The last survival follow-up date was November 01, 2015. Overall survival (OS) was calculated from the date of surgery to the date of death or last follow-up. Disease-free survival (DFS) was calculated from the date of surgery to the date of disease recurrence or metastasis or the last follow-up in localized RCC patients who underwent full resection.

Statistical analysis

Descriptive statistics of patients’ characteristics (i.e. age and BMI) were presented as mean ± SD (standard deviation). Comparisons between groups were performed using the Kruskal-Wallis or χ2 test. Pearson correlation was performed to evaluate the relationship of serum CRP and Alb with OS. The optimal cut-off points for the inflammation-based factors were determined by receive operating characteristic (ROC) analysis and the areas under the curve (AUC) were calculated. Survival analysis and curves were performed according to the Kaplan-Meier method and compared by the log-rank test. A Cox proportional-hazard model for multivariable analysis was applied for variables that proved to be significant in the univariate analysis. Hazard ratios (HR) with 95% confidence interval (95% CI) were also calculated using univariate or multivariate analysis. If variables were significantly associated with other variables, they were excluded from the final multivariable analysis. Statistical analyses were performed using IBM SPSS 21.0 software (IBM Corporation, Armonk, NY). Differences at p < 0.05 were considered to be significant in all statistical analyses.

Results

Patient demographics and outcomes

The clinicpathological characteristics of the 570 RCC patients were summarized in Table  1. Their mean age was 51.43 ± 13.52 years old and their mean and median follow-up periods were 65.19 and 63.54 months, respectively. Among them, 382 (67%) were males and 188 (33%) were females; 81 (14.2%) died and 489 (85.8%) survived at last follow-up. There were 451 (79.10%) patients with clear cell, 41 (7.20%) with papillary, 78 (13.70%) with others RCC (such as 27 (4.70%) with chromophobe, 10 (1.80%) with multilocular cystic, 41 (7.20%) with other histological types of RCC). The overall cancer-specific survival (CSS) was 93.1% at 1 year, 89.6% at 2 years, and 81.6% at 5 years.
Table 1
Baseline characteristics of all patients ( n = 570)
Characteristics
Cases ( n = 570)
Percentage (%)
Age (years) (Mean ± SD)
51.43 ± 13.52
BMI (Mean ± SD)
23.57 ± 3.59
Gender
 Male
382
67.00
 Female
188
33.00
Pathological types
 Clear cell carcinoma
451
79.10
 Papillary carcinoma
41
7.20
 Others
78
13.70
Fuhrman-grade
 I
119
20.90
 II
249
43.70
 III
60
10.50
 IV
7
1.20
 Unknown
135
23.70
pTNM stage
 I
397
69.60
 II
85
14.90
 III
59
10.40
 IV
29
5.10
pT status
 T1
407
71.40
 T2
94
16.50
 T3+ T4
69
12.10
pN status
   
 N0
535
93.90
 N1
35
6.10
pM status
 M0
550
96.50
 M1
20
3.50
Urine protein
 No
460
80.70
 Yes
28
4.90
 Unknown
82
14.40
ALP
 Normal
525
92.10
 Elevated
45
7.90
LDH
 Normal
468
82.10
 Elevated
102
17.90
CRE
 Normal
546
95.80
 Elevated
24
4.20
UA
 Normal
461
80.90
 Elevated
109
19.10
Total protein
 Normal
503
88.20
 Elevated
67
11.80
Serum globulin
 Normal
360
63.20
 Elevated
210
36.80
NLR
 < 1.85
242
42.50
  ≥ 1.85
328
57.50
PLR
 < 153
418
73.30
  ≥ 153
152
26.70
CRP/Alb
 < 0.08
393
68.90
  ≥ 0.08
177
31.10
Abbreviation: BMI body mass index, pTNM pathologic tumor–node–metastasis, ALP alkaline phosphatase, LDH lactate dehydrogenase, CRE serum creatinine, UA uric acid, LDH lactate dehydrogenase, NLR neutrophil count to lymphocyte count, PLR platelet count to lymphocyte count, CRP/Alb the serum CRP level to the serum Alb level

The relationship of serum CRP and Alb with OS

We explored the association of the serum CRP and Alb with OS. The results showed a significant negative correlation between serum CRP level and OS (r = −0.141, P < 0.001) (Additional file 1: Figure S1a) and a significant positive correlation between serum Alb level and OS (r =0.317, P < 0.001) (Additional file 1: Figure S1b).

The optimal cut-off value of inflammation-based factors by the ROC analysis

Based on the area under ROC curve (AUC) of 0.715 ( P < 0.001) for survival in the ROC analysis, the optimal cut-off value was 0.08 for CRP/Alb ratio. 1.85 for NLR and 153 for PLR, respectively. The sensitivity and specificity of CRP/Alb ratio were 66.7 and 75.1%, respectively. In addition, the ability to distinguish CRP/Alb ratio from other inflammation-based prognostic factors was compared using the levels of AUC. The results showed that was 0.675 and 0.704 for NLR and PLR, respectively (Fig.  1 and Additional file 2: Table S1). Based on the cut-off value of CRP/Alb ratio, 177(31.1%) patients were assigned into low CRP/Alb group and 393 (68.9%) patients were in the high CRP/Alb group.

The clinicopathological characteristics and the preoperative CRP/Alb ratio

The clinicopathological characteristics of all patients are described in Table  2. An elevated CRP/Alb ratio was significantly associated with the Fuhrman-grade ( P < 0.001), T stage ( P < 0.001), N stage ( P < 0.001), M stage ( P < 0.001), ALP ( P = 0.018), LDH ( P = 0.004), NLR ( P < 0.001) and PLR ( P < 0.001). For patients in the low CRP/Alb ratio group, 94.7% were at stag T1/T2 and 5.3% at stage T3/T4. However, for patients in the high CRP/Alb ratio group, only 72.9% patients were at stage T1/T2 and 27.1% at T3/T4 ( P < 0.001). Similarly, the percentage of patients at stage N0/N1 was 97.2%/2.8% and that of patients at stage M0/M1 was 99.2%/0.8% in patients in the low CRP/Alb ratio group. By comparison, the percentage of patients at N0/N1 was 86.4%/13.6% and at stage M0/M1 was 90.4%/9.6% in the high CRP/Alb ratio group ( P < 0.001). These results indicate that CRP/Alb ratio is associated with the disease progression and low CRP/Alb ratio is related with the early stage of RCC.
Table 2
Clinicopathological variables of patients according to the cutoff value of CRP/Alb ratio
Characteristics
CRP/Alb < 0.08
( n = 393)
CRP/Alb ≥ 0.08
( n = 177)
P value
Age (years)
48.71 ± 12.98
55.25 ± 13.92
<0.001 a
BMI
23.65 ± 3.37
23.41 ± 4.02
0.290 a
Gender
   
0.219 b
 Male
257 (65.40%)
125 (70.60%)
 
 Female
136 (34.60%)
52 (29.40%)
 
Pathological types
   
0.315 b
 Clear cell carcinoma
308 (81.20%)
43 (80.80%)
 
 Papillary carcinoma
26 (3.80%)
15 (8.50%)
 
 Others
59 (15.00%)
19 (10.70%)
 
Fuhrman-grade
   
<0.001 b
 I
92 (23.40%)
27(15.30%)
 
 II
178(45.30%)
71(40.10%)
 
 III
31(7.90%)
29(16.40%)
 
 IV
2(0.50%)
5(2.80%)
 
 Unknown
90(22.90%)
45(25.40%)
 
pTNM stage
   
<0.001 b
 I
313(79.60%)
84(47.50%)
 
 II
53(13.50%)
32(18.10%)
 
 III
22(5.60%)
37(20.90%)
 
 IV
5 (1.30%)
24(13.60%)
 
pT status
   
<0.001 b
 T1
318 (80.90%)
89 (50.30%)
 
 T2
54 (13.70%)
40 (22.60%)
 
 T3+ T4
21 (5.30%)
48 (27.10%)
 
pN status
   
<0.001 b
 N0
382 (97.20%)
153 (86.40%)
 
 N1
11 (2.80%)
24 (13.60%)
 
pM status
   
<0.001 b
 M0
390 (99.20%)
160 (90.40%)
 
 M1
3 (0.80%)
17 (9.60%)
 
Urine protein
   
0.188 b
 No
319 (81.20%)
141 (79.7%)
 
 Yes
15 (3.80%)
13 (7.3%)
 
 Unknown
59 (15.00%)
23 (13.00%)
 
ALP
   
0.018 b
 Normal
369 (93.90%)
156 (88.10%)
 
 Elevated
24 (6.10%)
21 (11.90%)
 
LDH
   
0.004 b
 Normal
335 (85.20%)
133 (75.10%)
 
 Elevated
58 (14.80%)
44 (24.90%)
 
CRE
   
0.001 b
 Normal
384 (97.70%)
162 (91.50%)
 
 Elevated
9 (2.30%)
15 (8.50%)
 
UA
   
0.468 b
 Normal
321 (81.70%)
140 (79.10%)
 
 Elevated
72 (18.30%)
37 (20.90%)
 
Total protein
   
0.144 b
 Normal
352 (89.60%)
151 (85.30%)
 
 Elevated
41 (10.40%)
26 (14.70%)
 
Serum globulin
     
 Normal
273 (69.50%)
87 (49.20%)
<0.001 b
 Elevated
120 (30.50%)
90 (50.80%)
 
NLR
   
<0.001 b
 < 1.85
205 (52.20%)
37 (20.90%)
 
  ≥ 1.85
188 (47.80%)
140 (79.10%)
 
PLR
   
<0.001 b
 < 153
324 (82.40%)
94 (53.10%)
 
  ≥ 153
69 (17.60%)
83 (46.90%)
 
Abbreviation: BMI body mass index, pTNM pathologic tumor–node–metastasis, ALP alkaline phosphatase, LDH lactate dehydrogenase, CRE serum creatinine, UA uric acid, LDH lactate dehydrogenase, NLR neutrophil count to lymphocyte count, PLR platelet count to lymphocyte count, CRP/Alb the serum CRP level to the serum Alb level
aKruskal-Wallis test
bChi-square test

The relationship between the preoperative CRP/Alb ratio and OS in all RCC patients

Compared with high CRP/Alb ratio, patients with low CRP/Alb ratio had longer OS (CRP/Alb˂0.08 vs. ≥0.08, mean OS: 164.87 vs 79.92 months, P˂0.001) (Fig.  2b). Similarly, longer OS was also observed in patients in the low CRP/Alb group at early stage T1/T2 (P˂0.001), at the advanced stage T3/T4 ( P = 0.003), at N0 (P˂0.001), N1( P = 0.006), M0 (P˂0.001) stages, but not at M1stage ( P = 0.869) (Fig.  3).
Table  3 shows the results of the univariate and multivariate analysis of OS. It is clear from the univariate analysis that the CRP/Alb ratio is associated with the OS of RCC patients (HR: 5.55; 95% CI: 3.48–8.86; P < 0.001). After excluding the related variables, the significant variables (age, BMI, T stage, N stage, M stage, NLR, PLR and CRP/Alb ratio) were tested in the multivariate analysis. The multivariate analysis indicated that the CRP/Alb ratio (HR: 1.94; 95% CI: 1.12–3.36; P =0. 018) is an independent prognostic factor for OS in addition to N stage (HR: 3.62; 95% CI: 1.91–6.85; P < 0.001), M stage (HR: 3.12; 95% CI: 1.57–6.19; P = 0.001) and PLR (HR: 2.42; 95% CI: 1.43–4.07; P < 0.001), but not LDH and NLR.
Table 3
Univariate and multivariate analyses for variables considered for overall survival (OS) (Cox proportional hazard regression model) ( n = 570)
 
OS Univariate analysis
OS Multivariate analysis
Characteristics
95% CIs
HR
P value
95% CIs
HR
P value
Age (years)
1.01 to 1.05
1.03
<0.001 a
1.01 to 1.05
1.03
<0.001 b
BMI
0.82 to 0.93
0.87
<0.001 a
0.84 to 0.97
0.91
0.007 b
Gender
 Male
 
1.00(ref.)
       
 Female
0.73 to 1.82
1.16
0.532 a
     
Pathological types
 Clear cell carcinoma
 
1.00(ref.)
   
1.00(ref.)
 
 Papillary carcinoma
1.36 to 4.72
2.53
0.003 a
0.67 to 4.39
1.72
0.258 b
 Others
0.70 to 2.42
1.30
0.414 a
0.64 to 3.99
1.60
0.312 b
Fuhrman-grade
 I
 
1.00(ref.)
   
1.00(ref.)
 
 II
0.68 to 2.82
1.39
0.365 a
0.72 to 3.21
1.52
0.269 b
 III
1.46 to 7.14
3.23
0.004 a
0.57 to 3.09
1.33
0.507 b
 IV
1.70 to 22.12
6.14
0.006 a
0.43 to 6.08
1.62
0.474 b
 unknown
1.25 to 5.19
2.55
0.010 a
0.43 to 2.55
1.05
0.922 b
pTNM stage
 I
 
1.00(ref.)
       
 II
1.27 to 4.85
2.48
0.008 a
     
 III
3.51 to 11.40
6.33
<0.001 a
     
 IV
14.54 to 46.54
26.01
<0.001 a
     
pT status
 T1
 
1.00(ref.)
   
1.00(ref.)
 
 T2
1.76 to 5.46
3.10
<0.001 a
1.20 to 3.90
2.16
0.011 b
 T3+ T4
4.72 to 12.92
7.81
<0.001 a
0.91 to 3.13
1.69
0.098 b
pN status
 N0
 
1.00(ref.)
   
1.00(ref.)
 
 N1
6.42 to 17.09
10.47
<0.001 a
1.91 to 6.85
3.62
<0.001 b
pM status
 M0
 
1.00(ref.)
   
1.00(ref.)
 
 M1
8.71 to 26.12
15.08
<0.001 a
1.57 to 6.19
3.12
0.001 b
Urine protein
 No
 
1.00(ref.)
       
 Yes
0.46 to 2.84
1.14
0.773 a
     
 Unknown
0.48 to 1.74
0.92
0.787 a
     
ALP
 Normal
 
1.00(ref.)
       
 Elevated
0.61 to 2.63
1.27
0.527 a
     
LDH
 Normal
 
1.00(ref.)
       
 Elevated
0.84 to 2.34
1.40
0.203 a
     
CRE
 Normal
 
1.00(ref.)
       
 Elevated
0.78 to 4.07
1.78
0.175 a
     
UA
 Normal
 
1.00(ref.)
       
 Elevated
0.77 to 4.08
1.78
0.176 a
     
Total protein
           
 Normal
 
1.00(ref.)
       
 Elevated
0.77 to 2.54
1.40
0.265 a
     
Serum globulin
 Normal
 
1.00(ref.)
   
1.00(ref.)
 
 Elevated
1.66 to 4.03
2.59
<0.001 a
0.84 to2.31
1.39
0.203 b
NLR
           
 < 1.85
 
1.00(ref.)
   
1.00(ref.)
 
  ≥ 1.85
3.08 to 11.59
5.97
<0.001 a
0.97 to 4.32
2.05
0.060 b
PLR
 < 153
 
1.00(ref.)
   
1.00(ref.)
 
  ≥ 153
3.49 to 8.56
5.46
<0.001 a
1.43 to 4.07
2.42
<0.001 b
CRP/Alb
 < 0.08
 
1.00(ref.)
   
1.00(ref.)
 
  ≥ 0.08
3.48 to 8.86
5.55
<0.001 a
1.12 to 3.36
1.94
0.018 b
Abbreviation: HR hazard ratio, CIs confidence intervals, BMI body mass index, pTNM pathologic tumor–node–metastasis, ALP alkaline phosphatase, LDH lactate dehydrogenase, CRE, serum creatinine, UA, uric acid, LDH lactate dehydrogenase, NLR neutrophil count to lymphocyte count, PLR platelet count to lymphocyte count, CRP/Alb the serum CRP level to the serum Alb level
aUnivariate Cox proportional hazard regression
bMultivariate Cox proportional hazard regression

The relationship between the preoperative CRP/Alb ratio and DFS in localized (T1-3 N0/+ M0) RCC patients underwent full resection

The clinicopathological characteristics of 541 localized (T1-3 N0/+ M0) RCC patients underwent full resection were summarized in Additional file 3: Table S2. CRP/Alb ratio was used to analyze the DFS of these patients, who were considered as received the curative treatment. Among them, patients with low CRP/Alb ratio had longer DFS event than patients in the high CRP/Alb ratio group (CRP/Alb˂0.08 vs. ≥0.08, mean DFS: 166.75 vs 85.58 months, P˂0.001) (Fig.  2a). In addition, DFS of patients at stages T1, T2, T3,N0 and N1 in the low CRP/Alb ratio group also had longer DFS event than patients in the high CRP/Alb ratio group ( P < 0.001, P = 0.032, P = 0.044, P < 0.001 and P = 0.004, respectively) (Fig.  4).
Table  4 showed the results of univariate and multivariate analyses of DFS. It is clear from the univariate analysis results that CRP/Alb ratio is associated with DFS of localized RCC patients underwent full resection (HR: 4.22; 95% CI: 2.54–7.02; P <0.001). The multivariate analysis also indicated that CRP/Alb ratio (HR: 2.14; 95% CI: 1.22–3.75; P = 0.008) is an independent prognostic factor for DFS of these patients. In addition, age (HR: 1.03; 95% CI: 1.01–1.06; P <0.001), BMI (HR: 0.89; 95% CI: 0.82–0.97; P = 0.005), N stage (HR: 4.70; 95% CI: 2.19–10.09; P <0.001) and PLR (HR: 2.44; 95% CI: 1.38–4.32; P =0 .002) are also independent prognostic factors for DFS of RCC patients.
Table 4
Univariate and multivariate analyses for variables considered for disease-free survival (DFS) (Cox proportional hazard regression model) ( n = 541)
 
DFS Univariate analysis
DFS Multivariate analysis
Characteristics
95% CIs
HR
P value
95% CIs
HR
P value
Age (years)
1.02 to 1.05
1.03
0.002 a
1.01 to 1.06
1.03
<0.001 b
BMI
0.79 to 0.93
0.86
<0.001 a
0.82 to 0.97
0.89
0.005 b
Gender
           
 Male
 
1.00(ref.)
       
 Female
0.57 to 1.66
0.97
0.921 a
     
Pathological types
           
 Clear cell carcinoma
 
1.00(ref.)
   
1.00(ref.)
 
 Papillary carcinoma
1.15 to 4.80
2.35
0.019 a
0.62 to 2.99
1.47
0.431 b
 Others
0.33 to 1.80
0.77
0.550 a
0.32 to 1.91
0.78
0.587 b
Fuhrman-grade
           
 I
 
1.00(ref.)
       
 II
0.62 to 2.68
1.28
0.504 a
     
 III
1.01 to 5.86
2.44
0.047 a
     
 IV
0.97 to 20.24
4.99
0.055 a
     
 unknown
0.68 to 3.40
1.53
0.299 a
     
pTNM stage
 I
 
1.00(ref.)
       
 II
1.33 to 4.84
2.54
0.005 a
     
 III
3.54 to 11.08
6.26
<0.001 a
     
pT status
 T1
 
1.00(ref.)
   
1.00(ref.)
 
 T2
1.57 to 5.03
2.81
<0.001 a
1.29 to 4.35
2.38
0.005 b
 T3
2.20 to 8.03
4.20
<0.001 a
0.65 to 2.72
1.33
0.437 b
pN status
 N0
 
1.00(ref.)
   
1.00(ref.)
 
 N1
3.72 to 13.73
7.15
<0.001 a
2.19 to 10.09
4.70
<0.001 b
Urine protein
           
 No
 
1.00(ref.)
       
 Yes
0.44 to 3.40
1.23
0.691 a
     
 Unknown
0.28 to 1.49
0.64
0.301 a
     
ALP
           
 Normal
 
1.00(ref.)
       
 Elevated
0.19 to 2.02
0.63
0.440 a
     
LDH
 Normal
 
1.00(ref.)
       
 Elevated
0.84 to 2.69
1.51
0.168 a
     
CRE
 Normal
 
1.00(ref.)
       
 Elevated
0.59 to 4.51
1.64
0.341 a
     
UA
 Normal
 
1.00(ref.)
       
 Elevated
0.44 to 1.69
0.86
0.654 a
     
Total protein
 Normal
 
1.00(ref.)
       
 Elevated
0.37 to 1.97
0.85
0.704 a
     
Serum globulin
 Normal
 
1.00(ref.)
   
1.00(ref.)
 
 Elevated
1.26 to 3.40
2.07
0.004 a
0.69 to 2.05
1.19
0.533 b
NLR
 < 1.85
 
1.00(ref.)
   
1.00(ref.)
 
  ≥ 1.85
2.06 to 7.58
3.95
<0.001 a
0.78 to 3.37
1.62
0.193 b
PLR
 < 153
 
1.00(ref.)
   
1.00(ref.)
 
  ≥ 153
2.54 to 6.92
4.19
<0.001 a
1.38 to 4.32
2.44
0.002 b
CRP/Alb
 < 0.08
 
1.00(ref.)
   
1.00(ref.)
 
  ≥ 0.08
2.54 to 7.02
4.22
<0.001 a
1.22 to 3.75
2.14
0.008 b
Abbreviation: HR hazard ratio, CIs confidence intervals, BMI body mass index, pTNM pathologic tumor–node–metastasis, ALP alkaline phosphatase, LDH lactate dehydrogenase, CRE serum creatinine, UA uric acid, LDH lactate dehydrogenase , NLR neutrophil count to lymphocyte count, PLR platelet count to lymphocyte count, CRP/Alb the serum CRP level to the serum Alb level
aUnivariate Cox proportional hazard regression
bMultivariate Cox proportional hazard regression

Discussion

In this study, we retrospectively analyzed the prognostic value of CRP/Alb ratio in 570 RCC patients received radical or partial nephrectomy in our institution. Among them, 541 patients with localized (T1-3 N0/+ M0) RCC and subjected to full resection were also analyzed. The results demonstrated that CRP/Alb ratio is an independent prognostic factor for patients with RCC.
Although the basal CRP level is affected by genetic and environmental factors [ 20, 21], CRP is produced mainly by hepatocytes and is regulated by pro-inflammatory cytokines, especially interleukin-6 [ 22]. Increased CRP level has been reported in many types of cancers [ 2325]. The potential mechanisms for the association of CRP with cancer have been proposed. (1) Tissue inflammation was caused by the tumor growth may result in increased CRP levels [ 26]. (2) The elevated CRP could be an indicative biomarker of immune responses to tumor antigens [ 27]. (3) Tumor cells could produce more inflammatory proteins including CRP [ 24] or enhanced interleukin-6 and interlukin-8 in tumor cells could indirectly increase CRP expression [ 28]. Jabs WJ et al. showed that activity of the IL-6/CRP network in RCC patients contributes to the acute-phase reaction in local inflammatory processes [ 29]. Other clinical data also showed that elevated CRP level is associated with poorer OS of RCC patients [ 30, 31] and CRP has a significant impact on OS of metastatic RCC patients treated with a tyrosine kinase inhibitor, either sunitinib or sorafenib [ 32, 33].
Hypoalbuminemia is not a perfect indicator of nutritional status because of its long half-life and the potential influence of system factors such as inflammation and stress on serum Alb. However, it is an easy, reproducible assessment and closely correlated with other markers of nutritional status [ 34]. In addition, serum Alb as a biomarker of protein-energy malnutrition can provide essential information that supplementary to BMI and changes in body weight, which may not accurately reflect the nutritional status due to normal limits [ 35]. Protein malnutrition can lead to edema, impaired organ function and immunosuppression. Moreover, preoperative hypoalbuminemia is associated with higher mortality in patients with underwent surgery for RCC [ 14, 36, 37].
Recently, CRP/Alb ratio has been used to predict the prognosis of several cancers [ 1618]. In this study, we used the ROC analysis to yield a 0.08 cutoff value for CRP/Alb ratio for predicting OS in RCC. Compared with the other systemic inflammatory markers NLR and PLR, CRP/Alb ratio has the highest AUC value ( P < 0.001). Univariate analyses showed that higher CRP/Alb ratio is associated with poorer prognosis ( P < 0.001). Patients with CRP/Alb ratio ≥ 0.08 had a 5.5-higher mortality risk than patients with CRP/Alb ratio < 0.08. Multivariate analyses also showed that CRP/Alb ratio is independently predictable factor for OS of patients with RCC ( P = 0.018). Furthermore, RCC patients at stage T1/T2, stage T3/T4, N0, N1 and M0, but M1, in the low CRP/Alb group had significantly longer OS than their counterparts in the high CRP/Alb group ( P < 0.001, P < 0.001, P < 0.001, P = 0.006 and P < 0.001, respectively). Therefore, low CRP/Alb ratio is associated with the early stage RCC disease and high CRP/Alb ratio present the advanced or metastatic RCC suggesting that CRP/Alb ratio could be a new prognostic indicator related to the progression of RCC. More importantly, CRP/Alb ratio is also a predictor for recurrence or metastasis of localized (T1-3 N0/+ M0) RCC patients underwent full resection. In general, T1/T2 is staged as localized disease in RCC. However, patients at T1-3N1M0 stages underwent full resection may be also considered to receive a curative therapy. So far, although target reagent clinical trials for localized (T1-3N1M0) RCC patients using adjuvant therapy including axitinib are ongoing, there is no standard therapy for those patients after surgery. Therefore, looking for predict markers for full resection in localized (T1-3/N1 M0) RCC patients can avoid excessive treatment and help clinicians to identify high-risk patients for closer follow-up. Multivariate analysis of these 541 patients after adjustment for other variables including cancer stage, CRP/Alb ratio was an independent prognostic factor for DFS of patients in full resection of localized RCC ( P = 0.008). Patients underwent full resection of localized RCC in the low CRP/Alb group showed significantly longer DFS than patients underwent full resection of localized RCC in the high CRP/Alb group ( P < 0.001). Further analyses also suggested that patients underwent full resection at T1, T2, T3, N0 and N1 stages in the low CRP/Alb group had longer DFS than their counterparts in the high CRP/Alb group. To our best knowledge, this is the first report showing that CRP/Alb ratio can predict the DFS of localized RCC underwent full resection. These results are crucial for clinicians to make a decision for full resection of localized RCC and important to increase the accuracy of the established prognostic factors. The study also demonstrates that CRP/Alb ratio may serve as a screening method to choose the appropriate follow-up strategy for patients with localized RCC underwent full resection.
Our findings have some clinical implications. Firstly, compared with the preoperative NLR and PLR, the preoperative CRP/Alb ratio is more effective and suitable prognostic indicator in patients with RCC. Secondly, according to the preoperative CRP/Alb ratio, patients with high risk can be selected for further management and treatment. Thirdly, our result can be used to stratify patients who are more likely to respond to biomarker-based enrichment strategy in future clinical trials. Our study also has several limitations. First, it is a retrospective and single-center study, which may limit the prognostic value of the CRP/Alb ratio. Therefore, a large-scale prospective validation study is needed. Second, several other factors that are influential to inflammation such as life styles and smoking status were not included in the study. Third, DFS was recorded based on radio-examination which may be longer than the actual DFS as some patients admitted to hospital only when they had obvious symptoms. In summary, this study demonstrated that CRP/Alb ratio is an independent predictor of OS for patients with RCC and can be used to predict the relapse or metastasis of localized RCC patients underwent full resection.

Conclusion

Overall, we demonstrate that preoperative CRP/Alb ratio is an independent prognostic marker for OS of RCC patients after radical or partial nephrectomy. In addition, preoperative CRP/Alb ratio could be used to predict DSF of localized RCC patients who underwent curative treatment and help clinicians to identify the high-risk patients for closer follow-up.

Acknowledgements

None.

Funding

This study was supported by grants from National Natural Science Foundation of China (Grant No. 81302224 and 81202013) and Medical Scientific Research Foundation of Guangdong Province, China (Grant No. B2012131). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

Due to ethical restrictions, the raw data underlying this paper are available upon request to the corresponding author.

Authors’ contributions

Conception and Design: ZFJ, HH, GSJ. Provision of Study Material or Patients: ZFJ, HH, GSJ, HXB, CQ. Collection and Assembly of Data: ZFJ, HH, GSJ, HXB, CQ. Data Analysis and Interpretation: ZFJ, HH, HXB, YGW, YK, DP, YYL, CD, ZZL. Manuscript Writing: ZFJ, HH, GSJ, HXB, CQ, QZK, LZW, XYF, ZM, LR. Final Approval of Manuscript: All the authors.

Authors’ information

Not applicable.

Competing interests

All the authors state they have no conflicts of interest.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This retrospective study was conducted in accordance with the standards of the Declaration of Helsinki and was approved by the Sun Yat-sen University Cancer Center research ethics committee (Number: GZR2016-100). All patients have provided written informed consent for their information to be stored and used in the hospital database.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Cancer 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise